Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald
June 3, 2026 6:51 AM
Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Summit Therapeutics plc (NASDAQ: SMMT).The analyst commented, "This morning, we ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
